Figure 2.

FABP5 inhibition produces anti-inflammatory and antinociceptive effects. A, WT, FABP4 KO, and FABP5 KO mice received intraplantar injections of carrageenan, and paw edema was measured 4 h later. The change in paw edema from baseline is indicated. *, p < 0.05 versus WT mice (n = 6). B, thermal withdrawal latencies in WT, FABP4 KO, and FABP5 KO mice before and 4 h after intraplantar injection of carrageenan. *, p < 0.05 versus WT mice after carrageenan injection (n = 9). C, CGRP release in sections of lumbar spinal cords obtained from carrageenan- and saline-injected WT mice. Mice received an intraplantar injection of carrageenan or saline, and CGRP release was measured 4 h later in spinal sections obtained from the ipsilateral (carrageenan-injected) or contralateral (saline-injected) side. **, p < 0.01 (n = 6). D, capsaicin evoked CGRP release in lumbar spinal slices from WT and FABP5 KO. Spinal sections were obtained as in C. CGRP release was quantified in ipsilateral (carrageenan-injected) slices before and after treatment with capsaicin (1 μm, 30 min). *, p < 0.05; **, p < 0.01; ***, p < 0.001 (n = 6). E, TNFα, IL-1β, and IL-6 levels in paws at baseline and 4 h after carrageenan injection. Mice were injected with vehicle or SBFI26 (20 mg/kg, i.p.) 30 min before carrageenan injection. Cytokine levels were normalized to baseline levels in WT mice. *, p < 0.05 versus carrageenan-injected WT mice (n = 6). F, PGE₂ levels in paws at baseline and 4 h after carrageenan injection in WT mice treated with vehicle or 20 mg/kg SBFI26 and in FABP5 KO mice. **, p < 0.01 versus carrageenan injected WT mice (n = 6). Error bars represent S.E.